Currently, global interest in glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is surging. Consequently, many Indian clinicians prescribe these medications for type 2 diabetes and weight management. However, recent observational reports have sparked concerns regarding a potential ischemic optic neuropathy risk associated with their use. Therefore, a new nationwide cohort study from Sweden provides crucial insights to help clarify this clinical dilemma. Specifically, researchers evaluated whether GLP-1 RAs actually increase the risk of anterior ischemic optic neuropathy (AION) compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
Evaluating the Ischemic Optic Neuropathy Risk in Sweden
Specifically, Swedish investigators monitored 107,518 GLP-1 RA initiators and 185,898 SGLT-2 inhibitor initiators between 2013 and 2024. Notably, the median follow-up period for patients was approximately 1.6 years. During this timeframe, only 62 GLP-1 RA users and 64 SGLT-2 inhibitor users developed anterior ischemic optic neuropathy. Thus, the overall occurrence of this condition remained exceptionally low in both treatment groups. For instance, at the one-year mark, the absolute risk stood at 0.04% for GLP-1 RA users versus 0.02% for SGLT-2 inhibitor users. Furthermore, at five years, the absolute risk increased to 0.12% versus 0.07%, respectively. Although the relative risk appeared higher for GLP-1 RA users, the absolute risk differences were remarkably tiny.
Accounting for Confounding by Diabetes Severity
Indeed, the researchers performed additional analyses to account for underlying differences in patient health. Specifically, they restricted their analysis to patients who were already receiving metformin at baseline. Because metformin use serves as a marker for more standardized diabetes severity, this adjustment reduced potential bias. Consequently, the observed risk differences were substantially attenuated. At five years, the risk ratio dropped to 1.23, and the confidence interval included one. Therefore, these results strongly suggest that the initial slight risk increase was likely due to residual confounding rather than a direct drug effect.
Clinical Implications for Practice in India
Currently, the prevalence of type 2 diabetes in India is rising rapidly, making GLP-1 RAs highly valuable therapeutic tools. However, local practitioners must weigh potential adverse events carefully. Fortunately, these nationwide findings from Sweden provide strong reassurance. Similarly, a separate target trial emulation in the United States reached very comparable conclusions. Indeed, both studies highlight that absolute risks of optic neuropathy are extremely small. As a result, clinicians do not need to avoid prescribing GLP-1 RAs due to eye safety concerns. Instead, they should focus on managing glycemic levels safely while monitoring patient vision during routine follow-ups.
Frequently Asked Questions
Q1: Does using GLP-1 receptor agonists significantly increase the risk of anterior ischemic optic neuropathy?
While relative risks appear slightly higher compared to SGLT-2 inhibitors, the absolute risk remains extremely small. Furthermore, additional analyses suggest that this small difference is likely due to residual confounding from diabetes severity rather than a direct side effect of the medication.
Q2: Should Indian doctors stop prescribing GLP-1 receptor agonists because of optic neuropathy concerns?
No, clinical experts advise against stopping these medications. Since the absolute risk of optic neuropathy is incredibly low, the well-established metabolic, cardiovascular, and weight-loss benefits of GLP-1 receptor agonists far outweigh this potential risk.
Q3: How did the researchers account for differences in diabetes severity in this study?
The researchers conducted restricted analyses focusing solely on patients who were taking metformin at baseline. By doing so, they balanced diabetes severity between the groups, which substantially attenuated the risk differences and made them statistically indistinguishable.
References
- Ueda P et al. Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study. Ann Intern Med. 2026 Jul 14. doi: 10.7326/ANNALS-25-02096. PMID: 42441962.
- Reynolds KR, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation. Ann Intern Med. 2026 Jul 14. doi:10.7326/ANNALS-25-00860.